Ispire Technology Inc's Stock Price Drops 7.1%

Business by 2FIRSTS.ai

Nov.17.2023

Ispire Technology Inc's Stock Price Drops 7.1%

Ispire Technology Inc (ISPR) shares plummeted 7.1% to $12.76 during trading on Thursday, with approximately 29,991 shares traded.

According to Dispatchtribunal, the stock price of Nasdaq-listed company Ispire Technology Inc (ISPR) fell by 7.1% during Thursday's (November 16th) trading session, reaching a lowest trading price of $12.76.

According to reports, approximately 29,991 shares were traded during the trading period, marking a significant decline of 56% compared to the daily average trading volume of 67,846 shares.

References:

[1] Ispire Technology (NASDAQ:ISPR) Trading Down 7.1%

Also Read:

[1] Ispire Technology Inc. Reports Strong Financial Performance in Q1 2024

#United States #Technology.#Ispire Technologies Inc.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Company TPB Q3 Earnings: Nicotine Pouch Sales Surge 628% YoY, First U.S. Production Line Planned

Turning Point Brands (NYSE: TPB) released its financial results for the third quarter of 2025, reporting strong revenue and profit growth driven by surging Modern Oral (nicotine pouch) sales. The company announced plans to establish its first U.S.-based white pouch production line in 2026, marking a key step toward manufacturing localization.

Nov.06 by 2FIRSTS.ai

RLX Technology Inc. (NYSE: RLX) Q3 2025 Financial Results: Net Revenue US$158.6 Million; International Business Accounts for 72%

RLX Technology Inc. (NYSE: RLX) announced its unaudited financial results for the third quarter of 2025. The company reported net revenue of RMB 1.13 billion, up 49.3% year-on-year, and adjusted net profit of RMB 295.4 million, up 1.4% quarter-on-quarter. International business contributed 72% of total revenue, reflecting robust financial performance and continued shareholder returns.

Nov.14

QISI’s Dongguan Factory Posts Recruitment Notice for Production Positions

QISI’s Dongguan factory has posted new production job openings, following earlier reports of a shutdown at its Zhuhai site.

Oct.15

Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval

Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.